EVO

AI Memo

Evotec SE

As of 2026-09-20/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q3/9M results test reduced guidance • 2026-11-05

Base target: $2 / p=45% prob

Biggest risk

Evotec's company release confirmed a severe outlook reset: revenue guidance fell from €700–780 million to €570–610 million, while adjusted EBITDA guidance moved from €0–40 million to negative €70–105 million. Variable partnership timing, delayed revenue conversion and continued losses leave visibility weak [#PR-2026-08-13].

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Commercial indicators are improving beneath weak reported results: Evotec's company release confirmed approximately 28% growth in D&PD base-business net sales excluding strategic partnerships, high Just–Evotec Biologics capacity utilization and initial Horizon savings. Successful H2 conversion and cost execution could produce substantial upside from the depressed ADR price [#PR-2026-08-13].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-20

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Commercial momentum converts into reported revenue
Horizon savings restore operating leverage
Commercial indicators are improving beneath weak reported results: Evotec's company release confirmed approximately 28% growth in D&PD base-business net sales excluding strategic partnerships, high Just–Evotec Biologics capacity utilization and initial Horizon savings.

BearKey bullets

Analyst-revision coverage, social sentiment, options skew, short interest and insider-transaction evidence are unavailable, reducing confidence in market-positioning conclusions.
FY2026 revenue and adjusted EBITDA guidance were cut sharply, raising the risk of further estimate reductions if H2 conversion slips [#PR-2026-08-13].
Foreign-exchange movements remain a material headwind, as shown by the gaps between reported and constant-currency results and guidance [#PR-2026-08-13].

WatchKey bullets

Q3/9M results test reduced guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=45%)

Target spread vs base: +55% / -48%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $2 (p=45%)Bear Target: $1 (p=30%)

Commentary

The operating evidence remains mixed but tilted negative. A direct fetch of Evotec's August 13 company release confirmed weak H1 profitability and sharply reduced guidance, alongside stronger D&PD base-business activity, high Just–Evotec Biologics capacity utilization and initial Horizon savings [#PR-2026-08-13]. The ADR declined approximately 7.5% from the prior baseline's $1.73 reference to the September 18 anchor of $1.60, but the packet does not establish a specific causal headline. Comprehensive post-reset analyst revisions are unavailable. Social, options, short-interest and employee-sentiment coverage are also unavailable and should not be interpreted as neutral readings.

As of 2026-09-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Commercial momentum converts into reported revenue
Horizon savings restore operating leverage

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$2 / p=45% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-09-20 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-11-05
Q3/9M results test reduced guidance
Evotec's scheduled November 5 interim statement should show whether improved customer activity is converting into revenue and whether the reduced FY2026 outlook remains achievable. The company's August 13 release reported H1 revenue of €300.1 million, adjusted EBITDA of negative €42.7 million, and updated guidance of €570–610 million in revenue and negative €70–105 million in adjusted EBITDA [#PR-2026-08-13] [#IR-2026-11-05].
Prob 85.00% • Move -6.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Commercial momentum converts into reported revenue
2026-12-31
Evotec's August 13 company release said D&PD base-business net sales excluding strategic partnerships increased approximately 28% year over year in H1, while Just–Evotec Biologics benefited from high capacity utilization and customer-base expansion. Conversion into stronger H2 revenue would support stabilization, but management said the financial benefits would take time to materialize [#PR-2026-08-13].
Prob 45% • Move 15% • Priced-in 30%

Long-term Catalysts

Months to a year

Horizon savings restore operating leverage
2027-12-31
Evotec's August 13 company release confirmed initial Horizon savings and an expected 2026 contribution of approximately 20–30% of the previously announced €75 million annual run-rate savings target, which is targeted by the end of 2027. Delivery alongside improved utilization could narrow losses, but the current EBITDA guidance makes execution proof essential [#PR-2026-08-13].
Prob 50% • Move 35% • Priced-in 20%

Risks

Analyst-revision coverage, social sentiment, options skew, short interest and insider-transaction evidence are unavailable, reducing confidence in market-positioning conclusions.
FY2026 revenue and adjusted EBITDA guidance were cut sharply, raising the risk of further estimate reductions if H2 conversion slips [#PR-2026-08-13].
Foreign-exchange movements remain a material headwind, as shown by the gaps between reported and constant-currency results and guidance [#PR-2026-08-13].
H1 adjusted EBITDA was negative €42.7 million, leaving the recovery dependent on utilization, revenue timing and disciplined Horizon execution [#PR-2026-08-13].
Management said improving commercial activity would take time to translate fully into financial results, limiting near-term visibility [#PR-2026-08-13].
The peer set is operational rather than tightly valuation-comparable because Evotec combines discovery services, partnered programs and biologics development and manufacturing.

Peers

Symbol	Summary
CRL	Charles River offers a useful read-through on outsourced discovery and early-development demand. Differences in scale, portfolio composition and ongoing business changes make it an imperfect direct peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-20

Loading AI feed…

Symbol

Summary

CRL

Charles River offers a useful read-through on outsourced discovery and early-development demand. Differences in scale, portfolio composition and ongoing business changes make it an imperfect direct peer.